Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561158 | 1.00 | ALDH1A1 (0.46) | ALDH1A1IMPDH2KDM4ELMNADDB1 | |
| SCHEMBL16092003 | 0.81 | KDM4E (0.41) | ALDH1A1IMPDH2KDM4EDDB1CRBN | |
| SCHEMBL5824142 | 0.80 | SSTR4 (0.41) | ALDH1A1IMPDH2KDM4ELMNADDB1 | |
| SCHEMBL717936 | 0.78 | KDM4C (0.53) | ALDH1A1KDM4ELMNAKDM4CHTT | |
| SCHEMBL20662238 | 0.78 | KDM4E (0.39) | ALDH1A1KDM4ELMNADDB1CRBN | |
| SCHEMBL18391535 | 0.78 | KDM4E (0.39) | ALDH1A1KDM4ELMNADDB1CRBN | |
| SCHEMBL8231479 | 0.78 | GLS (0.44) | ALDH1A1IMPDH2KDM4ELMNAKDM4C | |
| SCHEMBL27983748 | 0.77 | ALDH1A1 (0.38) | ALDH1A1IMPDH2KDM4ELMNAKDM4C | |
| SCHEMBL27964549 | 0.77 | ALDH1A1 (0.38) | ALDH1A1IMPDH2KDM4ELMNAKDM4C | |
| SCHEMBL6652043 | 0.77 | ALDH1A1 (0.38) | ALDH1A1IMPDH2KDM4ELMNAKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-110669107-A | Antibacterial peptide and preparation method thereof | 上海医药工业研究院 | 2020-01-10 | — | — | CN | claimed |
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024145662-A1 | 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS | ALTAY THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2005003147-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004002999-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002422-A2 | 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | PNP, NSUN2, RNGTT | ALDH1A1 3858/4885IMPDH2 147/4885KDM4E 2422/4885 |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | ALDH1A1 2919/4885IMPDH2 3509/4885KDM4E 4592/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | ALDH1A1 3506/4885IMPDH2 4276/4885KDM4E 2163/4885 |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | ALDH1A1 4145/4885IMPDH2 4756/4885KDM4E 2459/4885 |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | NSUN2, BCDIN3D, METTL16 | ALDH1A1 2796/4885IMPDH2 149/4885KDM4E 148/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ALDH1A1 2698/4885IMPDH2 374/4885KDM4E 1216/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ALDH1A1 344/4885IMPDH2 2474/4885KDM4E 2800/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885IMPDH2 1211/4885KDM4E 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.